PathMap Literature Based Discovery Engine

Share your Discovery:

Guaranteed to find unpublished literature based discoveries.

Clear Search

Experiment #00000127

Neuroinflammatory astrocyte subtypes in the mouse brain

Pathologic Processes _gates_from_pathologic_processes Gene Expression Regulation _gates_to_gene_expression_regulation _gates_from_gene_expression_regulation Biological Phenomena _gates_to_biological_phenomena _gates_from_biological_phenomena Neuroinflammatory Diseases _gates_to_neuroinflammatory_diseases
View Results
Experiment #00000119

Hypothesis: Considering PubMed #41177462, Intranasally administered GDEVs, specifically spermidine-modified ginger extracellular vesicles, may offer a multi-target therapeutic strategy for C9orf72-associated ALS by crossing the blood-brain barrier via olfactory routes to potentially deliver gene-editing components, support axonal translation, restore STMN2 expression, and attenuate neuroinflammation.

Spermidine _gates_from_spermidine Olfactory Bulb _gates_to_olfactory_bulb Drug Delivery Systems _gates_from_drug_delivery_systems Stathmin 2 _gates_to_stathmin_2 Eukaryotic Initiation Factor-5A _gates_from_eukaryotic_initiation_factor_5a
View Results
Experiment #00000101

Hypothesis: If Botox were injected into the nerve ending on the third toe on the left foot, the toxin can "climb" retrograde from toe through motor neurons eventually to the brain and temporarily inhibit vesicular docking "from toe to head", potentially allowing a timed pharmacological therapeutic window for toxic EV clearance through the lymph system instead of docking and seeding.

Botulinum Toxins, Type A _gates_from_botulinum_toxins__type_a Axonal Transport _gates_to_axonal_transport _gates_from_axonal_transport SNARE Proteins _gates_to_snare_proteins _gates_from_snare_proteins Lymphatic Vessel Endothelial Hyaluronan Receptor-1 _gates_to_lymphatic_vessel_endothelial_hyaluronan_receptor_1
View Results
Experiment #00000091

Context:A patient is brought into a remote aid station after an explosion inside a covert manufacturing facility. They have a known concussive blast injury, moderate skin irritation, and potential unknown chemical inhalation.Patient Clinical Presentation:Physical Trauma: Grade 2 concussion (confusion, mild disorientation, reactive pupils).Dermatological: Superficial skin burning and blistering across the forearms. The skin smells faintly of burnt almonds or cut grass.Respiratory/Systemic: Shortness of breath, mild tachypnea, and sudden, severe muscle twitching (fasciculations) that began 10 minutes post-exposure.Operational Constraint:Standard advanced diagnostics are unavailable. The primary treatment kit contains standard trauma items, atropine/pralidoxime (2-PAM) autoinjectors, sodium thiosulfate, hydroxycobalamin, and basic field-expedient wellness supplies.Scan Instructions:Run a single scan over the medical and toxicological corpus to map this multi-system presentation. Provide the following outputs using Veridical Enforcement:Differential Toxin Ranking: Based on the combination of blast concussion, skin burning, and the specific onset of muscle twitching vs. scent clues, identify and rank the top two most likely overlapping chemical exposure pathways.The Dynamic Counter-Response (The "If/Then" Fork): Map the exact treatment-response trap. If I suspect Toxin A and administer standard Countermeasure X (e.g., an anticholinergic like atropine), but the patient’s fasciculations instantly stop while their blood pressure dangerously spikes and pupils violently dilate, what secondary hidden pathway does this reaction reveal?Veridical Contraindications: Explicitly cite the exact physiological mechanisms and PubMed-grounded parameters where standard concussion management (e.g., specific fluid resuscitation volumes or sedatives) directly exacerbates the cellular hypoxia or neurotoxicity caused by the suspected chemical inhalants. Do not hallucinate or approximate citations.

Blast Injuries _gates_from_blast_injuries Toxicology _gates_to_toxicology Fasciculations _gates_from_fasciculations Cholinesterase Inhibitors _gates_to_cholinesterase_inhibitors
View Results
Experiment #00000090

Ferroptosis

Ferroptosis _gates_from_ferroptosis _gates_to_ferroptosis Spinal Cord Injuries _gates_from_spinal_cord_injuries Cell Death _gates_to_cell_death _gates_from_cell_death CD14 Antigen _gates_to_cd14_antigen
View Results
Experiment #00000065

Does pathologically seeded TDP-43 exit the retina via anterograde axonal transport along the optic tract to midbrain hubs, enter the systemic circulation inside extracellular vesicles, and subsequently traffic into pancreatic beta-cells to accelerate type 2 diabetes phenotypes?

TAR DNA-Binding Protein 43 _gates_from_tar_dna_binding_protein_43 Extracellular Vesicles _gates_to_extracellular_vesicles Systemic circulating EVs _gates_from_systemic_circulating_evs Insulin-Secreting Cells _gates_to_insulin_secreting_cells Axonal Transport _gates_to_axonal_transport
View Results
Experiment #00000063

What specific structural modifications to the pyrrolidinone scaffold led to improved potency against SARM1 compared to earlier inhibitor classes?

Pyrrolidinones _gates_from_pyrrolidinones SARM1 _gates_to_sarm1 Sterile Alpha and TIR Motif Containing 1 _gates_from_sterile_alpha_and_tir_motif_containing_1 Axonal Degeneration _gates_to_axonal_degeneration Molecular Structure _gates_from_molecular_structure
View Results
Experiment #00000059

Amyotrophic lateral sclerosis; Biomarkers; Clinical trials; Neuron-derived extracellular vesicles; Neuropathology; Pharmacodynamic biomarkers; Surrogate endpoints; TDP-43

Disease Progression _gates_from_disease_progression Biological Markers _gates_to_biological_markers _gates_from_biological_markers Proteomics _gates_to_proteomics Platform Data _gates_from_platform_data Patient Selection
View Results
Experiment #00000047

Does blast-induced mild traumatic brain injury (mTBI) drive progressive tau/TDP-43 seeding by disrupting astrocytic AQP4 glymphatic clearance and activating microglial cGAS-STING neuroinflammation? #mTBI #Glymphatic #cGASSTING

Blast Injuries _gates_from_blast_injuries Aquaporin 4 _gates_to_aquaporin_4 _gates_from_aquaporin_4 Glymphatic System _gates_to_glymphatic_system _gates_from_glymphatic_system Protein Aggregates _gates_to_protein_aggregates
View Results
Experiment #00000039

What is the current evidence for RGNEF (ARHGEF28) functioning as a primary upstream regulator of axonal transport and TDP-43 homeostasis in ALS, and how does the failure of this 'terminal tether' initiate the pathological continuum compared to downstream protein aggregation?

Metabolic Stress _gates_from_metabolic_stress Protein Aggregation _gates_to_protein_aggregation _gates_from_protein_aggregation RNA Metabolism _gates_to_rna_metabolism _gates_from_rna_metabolism Axonal Transport _gates_to_axonal_transport
View Results
Experiment #00000038

Map the direct mechanical and axonal transport pathways connecting intranasal administration or trigeminal nerve delivery to the clearance of TDP-43 aggregates in sporadic ALS, and the delivery of CRISPR-Cas/ASO gene therapies targeting C9orf72 hexanucleotide repeat expansions in the cerebellum and brainstem.

Intranasal Route _gates_from_intranasal_route Blood-Brain Barrier _gates_to_blood_brain_barrier C9orf72 Protein _gates_to_c9orf72_protein _gates_from_c9orf72_protein Brain _gates_to_brain Intranasal Administration
View Results

See all pathway research